meRfi®-GM
Cancer Immunotherapy / Immuno-Oncology
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
Cancer Immunotherapy / Immuno-Oncology has seen tremendous strides in the past 15 years, introducing several novel immunotherapeutic agents. Nevertheless, as the clinical practice has shown, significant challenges remain, with many patients responding sub-optimally to available therapeutic options
These immunotherapies, while promising, often fail as a result of immune-specific cancer evasion
Tumor immunotherapy is the fourth therapy after [surgery](brain://7eT_g1eJZ…
References (Sources)
- .01 Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)
- An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
- Engineered T-cell Receptor T Cells for Cancer Immunotherapy
- Progress in human tumour immunology and immunotherapy
- Recent advances with cyclin-dependent kinase inhibitors: therapeutic agents for breast cancer and their role in immunooncology
- Regulation of immunotherapeutic products for cancer & FDA’s role in product development & clinical evaluationReview
- Reversing T-cell exhaustion in immunotherapy: a review on current approaches and limitations